Skip to content
Search for:
About Us Lupin Pharmaceuticals 2023-08-08T16:18:38+05:30
About Us
ABOUT US
CORPORATE OVERVIEW
LEADERSHIP
MAJOR MILESTONES
CODE OF CONDUCT
COMPLIANCE & ETHICS PROGRAM
ABOUT LUPIN U.S. PRESENCE
Lupin U.S. Today
Lupin?s presence in the United States is comprised of a diverse workforce encompassing manufacturing, research and development, and commercial divisions for generics, complex generics, biosimilars and branded pharmaceuticals.
Maintaining a Flagship Generics Stance
Lupin has a strong and well-established generic presence in the United States, having entered the U.S. market in 2003 and maintaining a competitive edge in the list of top 5 generic pharmaceutical companies by prescriptions dispensed since 20101. Our strength in the U.S. generics market is an outgrowth of our multi-channel supply chain, which includes a state-of-the-art U.S. commercial manufacturing facility, robust international distribution, and strategic external partnerships.
GENERICS
Continued Focus on Innovative Product Development to Launch Successful
Brands and First-to-Market Biosimilars
Lupin?s U.S. product development pipeline includes complex inhalation, branded generics projects, and a specialty focus on women?s health. This diversified and productive pipeline helps drive growth across therapeutic areas.
PRODUCT DEVELOPMENT
Continued Focus on Innovative Product Development to Launch Successful Brands and First-to-Market Biosimilars
Lupin?s U.S. product development pipeline includes complex inhalation, branded generics projects, and a specialty focus on women?s health. This diversified and productive pipeline helps drive growth across therapeutic areas.
PRODUCT DEVELOPMENT
Investment in a Growing Specialty Presence
The launch of SOLOSEC? in 2018 kick-started Lupin?s expansion into the women?s health space, advancing one of our primary business objectives in the United States, which is to bring novel products to the market that address unmet medical needs. Lupin has created a talented, fully integrated Specialty Women?s Health commercial organization in the U.S. in order to build a solid foundation for continued specialty growth in the coming years.
SPECIALITY
1. IQVIA, National Prescription Audit (Rx), MAT August 2019 Data
? 2023 Lupin Pharmaceuticals, Inc. All Rights Reserved.
DO NOT SELL/SHARE MY PERSONAL INFORMATION |
PRIVACY |
PHARMACOVIGILANCE
DISCLAIMER |
SITEMAP |
NOTICE AT COLLECTION
?
DISCLAIMER
Information provided on this site is intended for use only by residents of the United States. The products discussed herein are available only upon prescription from a medical doctor or a qualified medical professional. Consumers should not construe any information herein as medical advice or as a substitute for discussions with a prescribing practitioner or other qualified medical professional. Reader understands and agrees to the foregoing.
facebook twitter instagram
DISCLAIMER
Information provided on this site is intended for use only by residents of United States. The products discussed herein are available only upon prescription from a medical doctor or qualified medical professional. Consumers should not construe any information herein as medical advice or as a substitute for discussions with a prescribing practitioner or other qualified medical professional. Reader understand and agrees to the foregoing.
PRODUCT LIS

Lupin Pharmaceutical?s generic and specialty presence in the U.S. includes 5 East Coast offices as well as a remote salesforce operating across the country.